sorafenib has been researched along with hymecromone in 1 studies
| Studies (sorafenib) | Trials (sorafenib) | Recent Studies (post-2010) (sorafenib) | Studies (hymecromone) | Trials (hymecromone) | Recent Studies (post-2010) (hymecromone) |
|---|---|---|---|---|---|
| 6,520 | 730 | 5,251 | 1,241 | 18 | 323 |
| Protein | Taxonomy | sorafenib (IC50) | hymecromone (IC50) |
|---|---|---|---|
| Testosterone 17-beta-dehydrogenase 3 | Homo sapiens (human) | 1 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Benitez, A; Bowen, T; Lokeshwar, VB; Shamaldevi, N; Yates, TJ | 1 |
1 other study(ies) available for sorafenib and hymecromone
| Article | Year |
|---|---|
Dietary supplement hymecromone and sorafenib: a novel combination for the control of renal cell carcinoma.
Topics: Animals; Apoptosis; Carcinoma, Renal Cell; Cell Proliferation; Dietary Supplements; Disease Models, Animal; Drug Therapy, Combination; Human Umbilical Vein Endothelial Cells; Hymecromone; Immunoblotting; Kidney Neoplasms; Mice; Mice, Nude; Niacinamide; Phenylurea Compounds; Random Allocation; Sensitivity and Specificity; Sorafenib; Treatment Outcome; Tumor Cells, Cultured; Xenograft Model Antitumor Assays | 2013 |